US Pharma MarketingEli Lilly raises 2026 outlook again as Q2 soars past estimates
Eli Lilly raises 2026 outlook again as Q2 soars past estimates is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Reporting 91% growth for Mounjaro, Lilly widened the gap to cardiometabolic rival Novo Nordisk.
Source: Pharmaceutical Technology